Market Access News | pharmaphorum

News

Vertex/CRISPR file first gene-editing therapy with FDA

Vertex Pharma and CRISPR Therapeutics have become the first companies to file for FDA approval of a therapy based on gene-editing technology.

News

BioNTech and Takeda add new ADCs to their pipelines

A pair of licensing deals today for BioNTech and Takeda provide further examples that antibody-drug conjugates (ADCs) are cementing their place as in the biopharma armamen

News

CHMP backs obesity drug Wegovy for teens

Novo Nordisk’s sought-after obesity drug Wegovy could be approved in the EU shortly for use in adolescents as well as adults.

News

Hutchmed files Takeda-partnered colorectal cancer drug in US

Chinese biotech Hutchmed has completed its rolling marketing application in the US for oral VEGF receptor inhibitor fruquintinib, which was licensed by Takeda for a hefty

News

GSK licenses out new HIV PrEP drug in poorer nations

GSK’s majority-owned HIV unit ViiV has agreed licensing deals with a trio of generic manufacturers to make its recently-approved long-acting drug for pre-exposure prophyla

News

NICE backs Keytruda for incurable cervical cancer via CDF

Hundreds of NHS patients with an incurable form of cervical cancer will be able to get treatment using a combination regimen based on Merck & Co/MSD’s cancer immunothe

Vertex/CRISPR file first gene-editing therapy with FDA

BioNTech and Takeda add new ADCs to their pipelines

CHMP backs obesity drug Wegovy for teens

Hutchmed files Takeda-partnered colorectal cancer drug in US

GSK licenses out new HIV PrEP drug in poorer nations

NICE backs Keytruda for incurable cervical cancer via CDF

Simple blood test could aid in global TB fight

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks